In Countersuit, Santaris Aims to Invalidate Isis Gapmer Patents | GenomeWeb

By Doug Macron

Santaris Pharma last week responded to a patent-infringement suit filed by Isis Pharmaceuticals, denying the allegations and asking the court hearing the case to invalidate the gapmer-related intellectual property at issue.

In its countersuit, Santaris asked for a court declaration that it does not infringe, directly or indirectly, two Isis patents, as well as a ruling that both pieces of IP are “invalid and unenforceable.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.